Everolimus: side effect profile and management of toxicities in breast cancer.

Breast cancer research and treatment

Volumn 140, Issue 3, 2013, Pages 453-462

  Paplomata, Elisavet ^a   Zelnak, Amelia ^b   O'Regan, Ruth ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EVEROLIMUS; MTOR PROTEIN, HUMAN; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CHEMICALLY INDUCED; FATIGUE; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; METABOLISM; PATHOLOGY; PNEUMONIA; STOMATITIS;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FATIGUE; FEMALE; HUMANS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; PNEUMONIA; SIROLIMUS; STOMATITIS; TOR SERINE-THREONINE KINASES;

EID: 84898703037     PISSN: None     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2630-y     Document Type: Review

References (0)